Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Teprotumumab-associated persistent unilateral hearing loss in dysthyroid optic neuropathy: a case report with review of the literature.

Endocrine journal·2026
Same author

Uncertainty in AI-driven Monte Carlo simulations.

Physical review. E·2026
Same author

AI-driven data-efficient estimation of partition functions in disordered materials.

Scientific reports·2026
Same author

Slowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential.

BMJ open diabetes research & care·2025
Same author

Fulminant and Slowly Progressive Type 1 Diabetes Associated with Pregnancy.

International journal of molecular sciences·2025
Same author

Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature.

The Kurume medical journal·2025

Related Experiment Video

Updated: May 23, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

ZnT8 and type 1 diabetes.

Eiji Kawasaki1

  • 1Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital, Nagasaki 852-8501, Japan. eijikawa@nagasaki-u.ac.jp

Endocrine Journal
|March 27, 2012
PubMed
Summary
This summary is machine-generated.

Autoantibodies to zinc transporter 8 (ZnT8A) are key markers in type 1 diabetes. This research highlights ZnT8

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Area of Science:

  • Endocrinology
  • Immunology
  • Genetics

Background:

  • Zinc transporter 8 (ZnT8) is crucial for insulin regulation in pancreatic beta-cells.
  • ZnT8 is a novel autoantigen in type 1 diabetes, with autoantibodies (ZnT8A) found in a significant percentage of patients.
  • Humoral autoreactivity to ZnT8 exhibits unique characteristics compared to other islet autoantigens.

Purpose of the Study:

  • To investigate the role of ZnT8 autoantibodies in type 1 diabetes pathogenesis.
  • To explore the impact of a specific genetic polymorphism (rs13266634) on ZnT8 autoantibody specificities.
  • To understand the relationship between ZnT8 humoral autoreactivity and clinical phenotypes in type 1 diabetes.

Main Methods:

  • Detection of autoantibodies to ZnT8 (ZnT8A) in patients with type 1 diabetes.
  • Analysis of the influence of the SLC30A8 gene polymorphism (rs13266634) on ZnT8A binding.
  • Correlation of ZnT8A levels and specificities with clinical characteristics of type 1 diabetes.

Main Results:

  • ZnT8A are prevalent in Japanese patients with type 1 diabetes (50-60% acute, 20% slow-onset).
  • A specific amino acid substitution (Arg325Trp) in ZnT8, linked to type 2 diabetes, critically affects ZnT8A binding.
  • Humoral autoreactivity to ZnT8 varies with clinical phenotype, suggesting a role in disease mechanisms.

Conclusions:

  • ZnT8 autoantibodies are important biomarkers for type 1 diabetes.
  • Genetic variations in ZnT8 influence autoimmune responses, impacting antibody binding.
  • Further research into ZnT8 autoreactivity may elucidate its role in type 1 diabetes pathogenesis.